证券代码：000790 证券简称：华神科技 公告编号：2025-008 成都华神科技集团股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第二十次会 议审议决定，公司将以现场表决与网络投票相结合的方式召开2024年年度股东大会。现 将有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次 （1）现场会议时间 2025年5月22日（星期四）下午14:00。 （2）网络投票时间 2025年5月22日，其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025 年5月22日9:15--9:25，9:30--11:30，13:00--15:00；通过深圳证券交易所互联网投票系统 投票的时间为：2025年5月22日9:15至15:00期间的任意时间。 5、会议召开及投票表决方式 本次股东大会采用现场表决与网络投票相结合的方式召开。 成都华神科技集团股份有限公司2024年年度股东大会 2、股东大会的召集人 董事会 3、会议召开的合法、合规性 本次 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-005 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届监事会第十 四次会议于2025年4月27日以现场会议的方式在公司会议室召开。本次会议通知 于2025年4月17日发出，应到监事3人，实到监事3人，会议由公司监事会主席苏 蓉蓉女士主持，本次会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 二、监事会会议审议情况 （一）审议通过《2024 年年度报告及其摘要》 经核查，监事会认为：公司《2024 年年度报告》全文及其摘要的编制和审 议程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网披露的相关公告文件。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 成都华神科技集团股份有限公司 第十三届监事会第十四次会议决议公告 本议案尚需提交 2024 年年度股东大会审议。 （二 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-004 成都华神科技集团股份有限公司 第十三届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第二 十次会议于2025年4月27日以现场与通讯表决相结合的方式在公司会议室召开。 本次会议通知于2025年4月17日发出，本次会议应出席董事9人，实际出席董事9 人。会议由公司董事长黄明良先生主持，公司全体监事、高级管理人员列席了 会议。本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《2024 年年度报告及其摘要》 董事会审议认为公司《2024 年年度报告》及《2024 年年度报告摘要》内容 真实、准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。本议案已 经公司董事会审计委员会审议通过。具体内容详见公司同日在巨潮资讯网披露 的相关公告文件。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-006 | 项目 | 本年度 | 上年度 | 上上年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 0 | 6,237,193.64 | 6,281,425.64 | | 回购注销总额（元） | 0 | 0 | 0 | | 归属于上市公司股东的净利润（元） | -6,690,166.26 | 27,659,463.93 | 41,217,518.38 | | 合并报表本年度末累计未分配利润（元） | | 215,897,052.82 | | | 母公司报表本年度末累计未分配利润（元） | | 235,768,607.78 | | | 上市是否满三个完整会计年度 | | 是 | | | 最近三个会计年度累计现金分红总额（元） | | 12,518,619.28 | | | 最近三个会计年度累计回购注销总额（元） | | 0 | | | 最近三个会计年度平均净利润（元） | | 20,728,938.68 | | | 最近三个会计年度累计现金分红及回购注销总 | | 12,518,619.28 | | | 额（ ...

Financial Performance - The company's operating revenue for 2024 was ¥863,976,571.55, a decrease of 13.89% compared to ¥1,003,376,637.04 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥6,690,166.26, representing a decline of 124.19% from ¥27,659,463.93 in the previous year[22] - The net profit after deducting non-recurring gains and losses was -¥15,563,890.23, down 143.94% from ¥35,421,382.66 in 2023[22] - The basic earnings per share for 2024 was -¥0.01, a decrease of 125.00% from ¥0.04 in 2023[22] - The weighted average return on net assets was -0.65%, down from 2.72% in the previous year[22] - The company reported a significant decline in both net profit and revenue, indicating potential challenges in its operational performance[22] - In Q1 2024, the company reported revenue of approximately ¥179.28 million, which increased to ¥278.56 million in Q2, but decreased to ¥205.24 million in Q3 and ¥200.90 million in Q4[26] - The net profit attributable to shareholders was ¥2.28 million in Q1, rising to ¥6.83 million in Q2, but turned negative with a loss of ¥3.37 million in Q3 and ¥12.43 million in Q4[26] - The total revenue for 2024 was approximately ¥863.98 million, representing a decrease of 13.89% compared to ¥1,003.38 million in 2023[61] Cash Flow and Assets - The net cash flow from operating activities increased by 35.57% to ¥64,278,831.37, compared to ¥47,414,104.46 in 2023[22] - Total assets at the end of 2024 reached ¥2,249,238,967.54, an increase of 5.43% from ¥2,133,478,855.05 at the end of 2023[22] - The net assets attributable to shareholders decreased by 0.71% to ¥1,025,895,578.65 from ¥1,033,194,655.74 in 2023[22] - The total cash inflow from financing activities increased by 38.94% to ¥680,067,649.83 in 2024, up from ¥489,464,280.26 in 2023[76] - The company's total assets included cash and cash equivalents of ¥209,467,279.68, accounting for 9.31% of total assets at the end of 2024[78] Government Support and Non-Recurring Gains - The company received government subsidies amounting to ¥5.63 million in 2024, up from ¥3.98 million in 2023, indicating a positive trend in government support[27] - The total non-recurring gains and losses for 2024 amounted to approximately ¥8.87 million, a significant recovery from a loss of ¥7.76 million in 2023[27] Market and Product Development - The pharmaceutical manufacturing industry in China is projected to maintain a revenue of ¥2.53 trillion in 2024, with a slight profit decline of 1.1%[30] - The company anticipates further market expansion and product innovation in response to the evolving healthcare landscape and consumer demands[30] - The health beverage market is expected to grow from ¥190 billion in 2019 to ¥310 billion by 2025, driven by health trends and innovative products[34] - The company has established a three-tier collaborative marketing network covering various regions in China, focusing on cardiovascular, ENT, and pediatric respiratory diseases, enhancing its competitive edge in these specialized treatment areas[35] - The core product, Sanqi Tongshu Capsule, was selected for the National Traditional Chinese Medicine Procurement Alliance in 2024 and is recommended in the "Guidelines for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine (2023 Edition)"[35] Research and Development - The company has applied for and acquired a total of 203 patents, with 168 authorized patents, including 4 international invention patents[47] - The company is advancing the development of a new product, Sanqi Tongshu Capsule, aimed at enhancing clinical value and market presence[73] - The number of R&D personnel increased to 166 in 2024, representing a growth of 23.88% compared to 134 in 2023[75] - R&D investment amounted to ¥28,178,452.75 in 2024, a decrease of 11.67% from ¥31,902,380.11 in 2023[75] Operational Efficiency and Management - The organization implemented a flat management structure to enhance operational efficiency, focusing on customer needs and market-driven strategies[59] - The company plans to strategically divest its steel structure business to concentrate resources on the core pharmaceutical industry[57] - The company has established a financial management center with a strict accounting system, ensuring independent financial decision-making without interference from shareholders[122] - The company has a complete internal management structure that operates independently from controlling shareholders[121] Environmental Management - The company has implemented strict environmental management practices, including obtaining necessary pollution discharge permits[169] - The pharmaceutical factory has been designated as a key wastewater discharge unit for 2024 in Chengdu, and has actively improved its environmental management level[172] - The company invested approximately 1.66 million yuan in environmental protection in 2024, covering clean production audits, online monitoring, and wastewater treatment operations[174] Shareholder Relations and Governance - The company held its first temporary shareholders' meeting in 2024 with a participation rate of 17.95% on January 31, 2024[123] - The company is committed to maintaining the legal rights of all shareholders through diligent board practices[143] - The board of directors approved a new compensation structure for executives, with an average increase of 15% in salaries[136] - The company has engaged in various investor relations activities to discuss business development and operational strategies throughout the reporting period[107] Strategic Commitments - The company has committed to avoiding any new competitive business activities with the listed company for a period of 5 years following the acquisition completion[182] - The company will take comprehensive measures, including asset injection and restructuring, to mitigate any potential adverse effects on the listed company due to overlapping business operations[182] - The company has pledged to avoid related party transactions with Taihe Health and its subsidiaries, ensuring fair and reasonable pricing[183]

Financial Performance - The company's revenue for Q1 2025 was CNY 126.91 million, a decrease of 29.21% compared to CNY 179.28 million in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of CNY 14.59 million, representing a decline of 740.09% from a profit of CNY 2.28 million in Q1 2024[6]. - The company reported a basic and diluted earnings per share of CNY -0.0234, a decrease of 750.00% from CNY 0.0036 in the same period last year[5]. - Total operating revenue decreased to ¥126,911,245.23 from ¥179,277,340.12, representing a decline of approximately 29.2% year-over-year[21]. - Net profit for the period was ¥-14,501,128.77, compared to a profit of ¥4,123,269.28 in the previous period, indicating a significant loss[22]. - Basic and diluted earnings per share were both ¥-0.0234, down from ¥0.0036 in the previous period[23]. Cash Flow and Operating Activities - The net cash flow from operating activities improved by 64.52%, with a net outflow of CNY 8.88 million compared to CNY 25.04 million in the previous year[5]. - Cash received from operating activities decreased by 85.97% to CNY 2.03 million, largely due to the previous year's receipt of development funds[12]. - The net cash outflow from operating activities was -$8,881,767.85, an improvement from -$25,035,659.98 in the previous period, indicating a reduction in cash burn[25]. - Cash inflow from operating activities totaled ¥203,075,400.26, down from ¥228,953,557.57, a decrease of approximately 11.3% year-over-year[24]. Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2.13 billion, down 5.26% from CNY 2.25 billion at the end of the previous year[5]. - The total assets decreased from 2,249,238,967.54 CNY to 2,130,996,832.61 CNY, a decline of approximately 5.3%[19]. - The total liabilities decreased from 1,200,000,000 CNY to 1,150,000,000 CNY, reflecting a reduction of about 4.2%[19]. - Total liabilities decreased to ¥1,077,403,955.40 from ¥1,181,257,849.14, a reduction of about 8.8%[20]. - Total equity attributable to shareholders decreased to ¥1,011,416,036.48 from ¥1,025,895,578.66, a decline of approximately 1.4%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,293[14]. - Sichuan Huasheng Group holds 17.87% of shares, amounting to 111,431,281 shares, with 89,033,593 shares pledged[14]. - The number of shareholders with more than 5% ownership remains stable, with no significant changes reported in the top 10 shareholders[15]. Operating Costs and Income - The company's operating costs decreased by 32.98% to CNY 66.81 million, primarily due to reduced business volume in the steel structure segment[11]. - Other income fell by 50.49% to CNY 2.44 million, mainly due to a reduction in government subsidies during the reporting period[11]. - Total operating costs decreased to ¥143,848,298.92 from ¥177,333,754.20, a reduction of about 18.9% year-over-year[21]. Investment and Financing Activities - The company reported a significant increase of 199.21% in cash received from financing activities, amounting to CNY 118.07 million, primarily due to financing lease receipts[13]. - Cash inflow from financing activities totaled $154,116,045.35, compared to $177,459,549.62 in the prior period, reflecting a decrease in financing received[25]. - The company reported a net investment loss of ¥-309,393.86, compared to a loss of ¥-1,114,592.88 in the previous period, indicating an improvement in investment performance[22]. Other Financial Metrics - Research and development expenses increased to ¥3,675,818.30 from ¥3,325,261.93, an increase of about 10.5% year-over-year[22]. - Cash paid to employees amounted to $33,626,517.12, an increase from $31,835,743.16, indicating rising labor costs[25]. - Cash paid for taxes was $25,301,530.36, a slight decrease from $27,121,071.62, suggesting improved tax efficiency[25]. - The company did not undergo an audit for the first quarter report, which may affect investor confidence in the financial statements[27].

Investment Rating - The report does not explicitly state an investment rating for the industry or the specific company being analyzed [1]. Core Insights - The company is focusing on the digitalization of traditional Chinese medicine (TCM) through AI technology to enhance production efficiency and quality [17]. - The company experienced a loss in 2024 due to several factors, including reduced project承接范围 in the construction steel structure segment, ongoing trial production in a project, goodwill impairment, and increased raw material costs affecting overall gross margin [17]. - The company plans to address rising raw material costs by closely monitoring market dynamics, implementing strategic procurement practices, and establishing partnerships with producers [19]. - The marketing strategy for 2025 includes simultaneous promotion in both hospital and retail markets, enhancing research and development efforts, and leveraging collective procurement policies to increase market penetration [20]. - The management is considering increasing the controlling stake in the company based on market conditions and regulatory policies [20]. - The company adheres to legal regulations regarding cash dividends while balancing shareholder returns with sustainable development [21]. - The impact of collective procurement on gross margins is acknowledged, with strategies in place to mitigate challenges and capitalize on opportunities [21]. - The company is contemplating divesting its steel structure business to focus on its core pharmaceutical operations [22]. Summary by Sections 1. Basic Research Information - The research was conducted on Huasheng Technology, a company in the TCM industry, on March 12, 2025, with participation from various investment institutions [13]. 2. Detailed Research Institutions - The research involved institutions such as Wanlian Securities, Zhiyuan Fund, Longfengfei Fund, and individual investors [14]. 3. Research Institution Proportions - Specific proportions of participating institutions are not detailed in the report [15]. 4. Main Content Information - The company showcased its product types and production processes during the visit [17]. - Key discussions included the company's digitalization efforts, reasons for recent losses, strategies for managing raw material costs, marketing plans for 2025, and potential changes in shareholding structure [17][19][20][21][22].

证券代码：000790 证券简称：华神科技 成都华神科技集团股份有限公司 投资者关系活动记录表 编号：2025-001 答：公司重视新技术对生产效率和生产质量的提升，公司内 部组织了针对 AI 的专项培训，公司正在积极探索和布局中医药 数字化领域，将 AI 技术深入应用到研发、生产、销售、职能等 多项领域和业务，促进各个板块高效化和智能化，持续增强公司 市场竞争力。感谢您的关注。 问 2：出现业绩亏损的主要原因？ 答：公司 2024 年业绩亏损主要是以下几方面原因：首先，建 筑钢结构板块严控项目承接范围，聚焦筛选现金流稳健的优质项 目，导致该板块产值和利润确认较去年大幅减少；其次，山东凌 凯在建项目尚处于试生产调试阶段，未实现产品销售，产生折旧 摊销费用；再次，初步经评估需确认商誉减值，并据此计提了相 应的商誉减值准备；最后，2024 年公司坚定聚焦医药主业，医药 业务营业收入较去年增长，但由于市场竞争激烈，中药原材料采 购价格持续攀升，致使整体毛利率呈下滑态势。这些因素共同影 响了公司短期财务表现。感谢您的关注。 问 3：公司如何应对中药原材料价格波动，原材料成本不断 上涨的风险？ 答：您好，药材价格上涨影 ...

Financial Performance - The company expects a net loss of between 8 million and 15.5 million yuan for the fiscal year 2024, compared to a profit of 27.66 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 10 million and 19.5 million yuan, down from a profit of 35.42 million yuan last year [2]. Factors Affecting Profit - The decline in overall net profit is attributed to increased competition, rising procurement costs of traditional Chinese medicine raw materials, and a reduction in the scale of the construction steel structure business [4]. - The construction steel structure segment's output and profit recognition significantly decreased due to a focus on high-quality projects and a streamlined project scope [4]. - The Shandong Lingkai project is still in the trial production phase, resulting in depreciation and amortization expenses without product sales [4]. Goodwill and Financial Reporting - The company has preliminarily assessed the need to recognize goodwill impairment, leading to the provision for goodwill impairment [5]. - The financial data presented is a preliminary estimate by the company's finance department and has not yet been audited by an external auditor [6]. - Investors are advised to exercise caution as the specific financial data will be detailed in the 2024 annual report [6].

证券代码：000790 证券简称：华神科技 公告编号：2024-067 关于接受间接控股股东财务资助暨关联交易的公告 成都华神科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 为支持成都华神科技集团股份有限公司（以下简称"公司"或"华神科技"）经营发展 资金需求，公司间接控股股东四川星慧酒店管理集团有限公司（以下简称"星慧集团"） 拟向公司提供不超过6,000万元（含）的无息借款，根据实际经营情况，在借款有效期 限内随借随还，额度循环使用，借款有效期至2025年12月16日。 星慧集团为公司间接控股股东，根据《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关规定，本次借 款事项构成关联交易，但属于公司接受关联人无偿提供财务资助，可豁免提交股东大会 审议。 公司于2024年12月23日召开了第十三届董事会第十九次会议、第十三届监事会第十 三次会议，会议审议通过了《关于接受间接控股股东财务资助暨关联交易的议案》，关 联董事已回避表决，全体非关联董事一致通过该议案。公司独立 ...